Vascular endothelial growth factor-A (VEGF-A) is highly subjected to alternative pre-mRNA splicing that generates several splice variants. The VEGF xxx and VEGF xxx b families encode splice variants of VEGF-A that differ only at the level of six amino acids in their C-terminal part. The expression level of VEGF xxx splice variants and their function as pro-angiogenic factors during tumor neo-angiogenesis have been well-described. The role of VEGF xxx b isoforms is less well known, but they have been shown to inhibit VEGF xxx -mediated angiogenesis, while being partial or weak activators of VEGFR receptors in endothelial cells. On the opposite, their role on tumor cells expressing VEGFRs at their surface remains largely unknown. In this study, we find elevated levels of VEGF 165 b, the main VEGF xxx b isoform, in 36% of non-small cell lung carcinoma (NSCLC), mainly lung adenocarcinoma (46%), and show that a high VEGF 165 b/VEGF 165 ratio correlates with the presence of lymph node metastases. At the molecular level, we demonstrate that VEGF 165 b stimulates proliferation and invasiveness of two lung tumor cell lines through a VEGFR/β1 integrin loop. We further provide evidence that the isoformspecific knockdown of VEGF 165 b reduces tumor growth, demonstrating a tumor-promoting autocrine role for VEGF 165 b in lung cancer cells. Importantly, we show that bevacizumab, an anti-angiogenic compound used for the treatment of lung adenocarcinoma patients, increases the expression of VEGF 165 b and activates the invasive VEGFR/β1 integrin loop. Overall, these data highlight an unexpected role of the VEGF 165 b splice variant in the progression of lung tumors and their response to anti-angiogenic therapies.
ARTICLE
VEGF 165 b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop 
Introduction
Angiogenesis is a complex process that contributes to various pathologies including cancer [1, 2] . Vascular endothelial growth factor-A (VEGF-A) is secreted by tumor cells and plays a crucial role in different aspects of tumorinduced angiogenesis. Binding of VEGF-A to its cognate tyrosine kinase receptors VEGFR-1 (Flt-1) or VEGFR-2 (Flk-1/KDR) and their co-receptors neuropilin-1 and neuropilin-2 promotes the activation of downstream signaling pathways that control proliferation, survival, and migration of endothelial cells during neo-angiogenesis [3, 4] . It has become apparent that the function of VEGF-A is not restricted to angiogenesis and vascular permeability [5] . Besides acting on endothelial cells through paracrine signaling, VEGF-A also impacts tumor cells themselves, especially those that express VEGF receptors and These authors contributed equally: Cherine Abou Faycal, Tao Jia.
neuropilins, including lung tumors [6] . Such VEGF-A autocrine signaling is essential for tumor initiation, survival, proliferation, or invasion as it promotes de-differentiation and epithelial to mesenchymal transition, but also because it regulates the self-renewal of cancer stem cells [7] [8] [9] [10] . Recent studies have revealed VEGF-A biology to be even more complex. As an example, VEGF-A prevents tumor cell invasion and mesenchymal transition in glioblastoma through the activation of a MET/VEGFR2 signaling pathway [11] . In early squamous lung carcinoma patients, a combination of high levels of VEGF-A, VEGFR1, and VEGFR2 is associated with a better rather than a worse outcome [12] . VEGF-A is expressed as multiple isoforms that result from pre-mRNA alternative splicing [13] . Two families of isoforms, VEGF xxx and VEGF xxx b are generated through the use of alternative 3' splice acceptor sites in exon 8 [14, 15] . This leads to the synthesis of proteins with the same length as the VEGF xxx isoforms, but with a distinct Cterminal domain. Owing to the absence of basic carboxyterminal amino acids essential for neuropilin-1 binding, VEGF 165 b, the main VEGF xxx b isoform, is able to itself stimulate some VEGFR signaling [16] [17] [18] . However, it cannot trigger a strong and sustained activation of VEGFR2, and it is also able to prevent VEGF 165 signaling that results in angiogenesis in endothelial cells [14, [19] [20] [21] [22] . Therefore, VEGF xxx b isoforms inhibit the phosphorylation and angiogenic capacity of VEGF xxx isoforms. In various tumors such as melanoma [20] , a decrease of VEGF 165 b correlates with a poor prognosis. On the opposite, high levels of VEGF xxx b proteins have been observed in some tumors, such as infiltrating ductal breast carcinoma [17] . Up till now, it is not known whether VEGF 165 b impacts tumor cells themselves that express VEGFR receptors.
Owing to the crucial role of neo-angiogenesis in tumor development, several anti-angiogenic therapies have been developed that inhibit either VEGF-A binding or VEGFR tyrosine kinase activity. However, these therapies modestly improve the overall survival (OS). Recent studies have highlighted VEGF-A pre-mRNA splicing as a potential reservoir for predictive biomarkers to anti-angiogenic therapies. As an example, high plasma levels of the shortest and most diffusible VEGF-A isoform (VEGF 121 ) were correlated with improved progression free survival (PFS) and/or OS in breast, gastric, or pancreatic cancer patients treated with the humanized monoclonal anti-VEGF-A antibody, bevacizumab [23, 24] . In addition, metastatic colorectal cancer patients with a low VEGF 165 b:VEGF total tumor ratio had a better outcome when treated with the combination of the FOLFOX4 chemotherapeutic protocol with bevacizumab compared with FOLFOX4 alone [25] . Therefore, deciphering the expression pattern and specific functions of VEGF xxx and VEGF xxx b splice isoforms in tumors might be critical when considering the response to these therapies.
Results
Human lung adenocarcinomas express high levels of VEGF 165 b
In order to analyze the status of VEGF 165 b and its proangiogenic counterpart VEGF 165 in lung tumors, we first performed immunohistochemistry in a series of normal lung parenchyma tissues and 76 NSCLCs, including 41 adenocarcinomas (ADC) and 35 squamous cell lung carcinomas (SCC) using specific anti-VEGF 165 and anti-VEGF 165 b antibodies we generated in the laboratory (see Materials and methods and Supplementary Figure 1a) . In the normal lung, a moderate diffuse cytoplasmic staining of both VEGF 165 and VEGF 165 Figure 2 ). Higher intra-tumoral (Fig. 1c) or circulating (Fig. 1d ) VEGF 165 b levels were specifically observed in lung adenocarcinoma patients, as compared with squamous lung carcinoma or healthy control subjects, respectively. In addition, elevated levels of VEGF 165 Table 1 ), indicating that both isoforms are not expressed in the same way. Importantly, we noticed that a high VEGF 165 b:VEGF 165 ratio correlates with lymph node metastases in NSCLC (Fig. 1e) . Collectively, these results suggested that high levels of VEGF 165 b are associated with NSCLC aggressivity.
VEGF 165 b promotes cell proliferation and lung adenocarcinoma growth
To deepen the functions of VEGF 165 b in non-small cell lung carcinoma, we generated stable VEGF 165 b-overexpressing clones in two cellular models derived from lung adenocarcinoma, namely H358 and H1299. These clones secreted high level of VEGF 165 b (Supplementary Figure 3a) and proliferated faster than their control counterparts (Fig. 2a) . Increased cell proliferation was also observed when the conditioned medium derived from these clones was applied to the native cells (Fig. 2b) , or when the cells were treated with recombinant human VEGF 165 b ligand (rhVEGF 165 b) (Fig. 2c) . On the other hand, transfecting cells with a siRNA specifically targeting the VEGF 165 b isoform diminished cell proliferation compared with control mismatch transfected cells (Fig. 2d) . Taken together, these data provided the first evidence that VEGF 165 b stimulates the proliferation of lung tumor cells. To validate the results in vivo, we designed subcutaneous xenograft experiments in nude mice using H1299 cells stably overexpressing VEGF 165 b or H358 cells stably expressing the splicing factor SRSF6. Hence, SRSF6 was previously reported to physiologically induce VEGF 165 b expression in primary epithelial cells [26] . We confirmed increased expression of VEGF 165 b in H358-derived SRSF6 overexpressing cells compared with H358 control cells, despite a reduction in overall VEGF-A level (Supplementary Figure 4a ). In addition, HUVEC cells cultured with conditioned medium of the SRSF6 clones were unable to form tubes in the matrigel, which was consistent with the anti-angiogenic properties of secreted VEGF 165 b (Supplementary Figure 4b ). Importantly, we observed that both H1299-VEGF 165 b and H358-SRSF6 xenografts grow faster than the control tumors ( Supplementary Figures 3b and 4c ), To eliminate unspecific effects related to VEGF 165 b overexpression, we designed a reverse in vivo experiment, in which H358 cells were subcutaneously injected into nude mice, allowed to form tumors. Mice were then subdivided in two groups that received either PBS + mismatch siRNA (Fig. 2e) . In agreement with a role of VEGF 165 b in lung tumor growth, tumors deprived of VEGF 165 b were smaller than control mismatch ones (Fig.  2f) . Level of hypoxia analyzed by CAIX or HIF1-alpha immunostaining (Supplementary Figure 5) , or tumor neoangiogenesis assessed by CD31 or α−SΜΑ endothelial staining (data not shown) was not different between control tumors and tumors deprived of VEGF 165 b. These results strongly suggested that tumor growth inhibition is not associated with decreased neo-angiogenesis. Consistently, the knockdown of VEGF 165 b in H358-derived xenografts significantly decreased KI67 staining compared with control xenografts (Fig. 2g) . As a whole, these data demonstrated that VEGF 165 b stimulates lung tumor proliferation and strongly suggested that autocrine rather than paracrine mechanisms are involved.
VEGF 165 b activates a VEGFR-dependent autocrine loop to promote tumor cell proliferation
We previously showed that lung adenocarcinoma expresses VEGFR1 and VEGFR2, and neuropilin-1 and neuropilin-2 receptors [6] . Therefore, we tested the impact of VEGF 165 b on VEGFR signaling in our lung tumor cells. We detected a persistent accumulation of activated P-VEGFR1(Tyr1213), P-VEGFR2(Tyr1054/1059), and P-VEGFR2(Tyr1214) proteins in H358 and H1299 cells treated for 72 h with rhVEGF 165 b (Figs 3a, b) . Same results were found in H358 and H1299 clones overexpressing VEGF 165 b (Figs 3c, d ). Of note, the activation of VEGFR1/VEGFR2 receptors was detectable at 24 h of rhVEGF 165 b treatment, but was not clearly observed at earlier time points (Supplementary Figure 6) . The activation of VEGFR1 and VEGFR2 was associated with the downstream accumulation of P-ERK1/2 ( Fig. 3a-d) , and the inhibition of ERK signaling by the use of U0126, a MEK1 pharmacological inhibitor, slowed down the cell proliferation of H358-VEGF 165 b clones (Fig. 3e) . Same results were obtained in H1299-VEGF 165 b clones (data not shown). Taken together, these results demonstrated that VEGF 165 b triggers a sustained activation of VEGFR receptors that correlates with ERK1/2 activation and cell proliferation. Importantly, the knockdown of VEGF 165 b strongly decreased P-VEGFR1(Tyr1213) immunostaining in H358-derived xenografts (Fig. 3f) , whereas the overexpression of VEGF 165 b in H1299-derived xenografts ( Supplementary Figures 3c and 3d ) or in SRSF6-expressing H358 xenografts (Supplementary Figure 4e) increased P-VEGFR1(Tyr1213) and P-VEGFR2(Tyr1214) protein levels. These data indicated that VEGF 165 b may stimulate tumor growth in vivo through the activation of VEGFR1 and VEGFR2. Of note, we were not able to assess the phosphorylation status of VEGFR2 in xenografts as the antibody did not give a specific immunostaining pattern. Furthermore, we observed that VEGFR1 and/or VEGFR2 mRNA levels increase in cells treated with rhVEGF 165 b ( Fig. 3g ) and in clones overexpressing VEGF 165 b (Fig. 3h ). These data indicated that VEGF 165 b also positively regulates total VEGFR expression. Consistently, VEGFR1 immunostaining decreased in H358-derived xenografts deprived of VEGF 165 b compared with control xenografts Figure 3d) , as well as in H358-SRSF6 xenografts (Supplementary Figure 4e ). Furthermore, we found that H1299-VEGF 165 b clones close wounds faster than the control cells (Fig. 4d) . Of note, H358 cells were not tested in wound healing assay, as they never reach confluency when grown in Petri dishes. However, in transwell assays, H358-VEGF 165 b clones transmigrated more efficiently than control cells (Fig. 4e) . H1299-VEGF 165 b clones also produced more pro-MMP9 and active MMP9 metalloproteinases (Fig.  4f) . Moreover, a reorganization of the actin cytoskeleton in stress fibers was observed in cells overexpressing VEGF 165 b (Fig. 4g ) or cultured with rhVEGF 165 b (Fig. 4h ). Cells exposed to rhVEGF 165 b also had more focal adhesions (Fig. 4i) . As a whole, these results demonstrate that VEGF 165 b promotes an invasive phenotype in H358 and H1299 lung adenocarcinoma cells.
VEGF 165 b stimulates an invasive β1 integrin/ VEGFR2 signaling pathway, which triggers the formation of actin stress fibers and focal adhesions
Next, we undertook a series of experiments to decipher the molecular mechanism(s) by which VEGF 165 b exhibits invasive properties. In endothelial cells, Chen and colleagues previously reported that matrix-bound VEGF 165 is able to maintain the phosphorylation of VEGFR2 on its tyrosine 1214 residue, leading to sustained activation of phosphop38 MAPK. Such effects were dependent on the association of VEGFR2 with β1 integrin [27] . In our cellular models, we reproducibly observed that rhVEGF 165 b triggers a sustained activation of P-VEGFR2(Tyr1214) (Fig. 3a-d) . We also noticed the activation of p38 MAPK in H358-VEGF 165 b clones together with the expression of phospho-FAK and phospho-cofilin proteins, two targets of β1 integrin signaling involved in actin polymerization (Fig.  5a ). Therefore, we postulated that the effects of VEGF 165 b could be mediated through the modulation of β1 integrin expression and/or activation. (Fig. 5c ), whereas the total amount of β1 integrin was not changed by any of the treatments. In agreement with a role of VEGF 165 b on β1 integrin activation, cell-surface-activated β1 integrin slightly increased in H358 or H1299 cells treated with rhVEGF 165 b compared with untreated cells (Fig. 5d) . Altogether, these observations were consistent with the idea that VEGF 165 b activates β1 integrin to mediate its biological effects. To confirm the role of β1 integrin, we used specific siRNA. We showed that β1 integrin neutralization prevents the formation of actin stress fibers (Fig. 5e ) and focal adhesions ( Fig. 5f ), cell migration (Fig. 5g) , and accumulation of phospho-VEGFR2(Tyr1214) and phosphop38MAPK proteins (Fig. 5h) 
Bevacizumab increases VEGF 165 b expression and promotes an invasive phenotype in lung cancer cells
Although the humanized monoclonal antibody against VEGF-A, bevacizumab, is currently used in the clinic for the treatment of lung adenocarcinoma patients, the results are disappointing and the molecular mechanisms involved in tumor escape remain largely unknown. Interestingly, we showed that bevacizumab induces a dose-dependent intra-cellular accumulation of the VEGF 165 b protein in H358 cells (Fig. 6a ). In contrast, the level of pan-VEGF-A decreased in the same conditions (Fig. 6a) . Same results were obtained using semaxanib (SU5416), a VEGFR tyrosine kinase inhibitor (Fig. 6b) , and in H1299 cells (data not shown). Furthermore, treatment of human H358 xenografts in mice with bevacizumab upregulated intra-tumoral VEGF 165 b protein level, as detected by immunohistochemistry (Fig. 6c) . Bevacizumab is currently used in combination with platinum salts for the treatment of NSCLC patients. We showed that cisplatin also increases the expression level of VEGF 165 b in lung adenocarcinoma cell lines (Fig. 6d) . Interestingly, a stronger accumulation of VEGF 165 b occurred upon co-treatment with cisplatin and bevacizumab (Fig. 6d) , and an elevated VEGF 165 b:VEGF-A total ratio was observed in the sera of 4/10 lung adenocarcinoma patients following bevacizumab/cisplatin treatment (Supplementary Figure 7a , patients 6, 7, 9, and 10). VEGF-A total in the sera of treated patients (data not shown). As a whole, these results are the first evidence that anti-angiogenic therapies used alone or in combination with cisplatin increase the expression of VEGF 165 b. Of note, the specific neutralization of VEGF 165 b in lung adenocarcinoma cell lines increased caspase-3 cleavage in response to cisplatin (Supplementary Figure 7b) , suggesting that VEGF 165 b could also act as an inhibitor of apoptosis.
At the molecular level, we observed that bevacizumab induces the accumulation of phosphorylated VEGFR1/ VEGFR2 and p38 MAPK in both H358 and H1299 cells (Fig. 6e and Supplementary Figure 8a) . This was prevented by the specific knockdown of VEGF 165 b. Increased P-VEGFR1(Tyr1213) immunostaining was also observed in bevacizumab-treated H358 xenografted mice that was prevented by the knockdown of VEGF 165 b (Supplementary  Figure 8b) . These results clearly indicated that bevacizumab activates the VEGF 165 b/VEGFR autocrine loop in H358 and H1299 lung adenocarcinoma cell lines. We did not detect any significant effect of bevacizumab in vitro on ERK1/2 activation ( Fig. 6e and Supplementary Figure 8a) or cell proliferation (data not shown), nor on tumor growth in vivo (data not shown). However, the knockdown of VEGF 165 b by siRNA significantly prevented the growth of bevacizumab-treated tumors, indicating that VEGF 165 b is required for tumor growth both in untreated (Fig. 2f) and bevacizumab-treated (data not shown) H358 xenografts. In addition, treatment of H1299 cells with bevacizumab for a long period of time (7 days) induced the expression of EMT markers, such as N-cadherin, vimentin, fibronectin, and α −SΜΑ proteins (Supplementary Figure 8c) . Although less pronounced, increased expression of vimentin was observed in H358 cells after 3 days of treatment (Fig. 6e) , as well as in bevacizumab-treated H358 xenografts ( Supplementary  Figure 8b) . Furthermore, H358 cells exposed to bevacizumab also had more focal adhesions (Fig. 6f) and more actin stress fibers (Fig. 6g) . All these events were prevented by the neutralization of VEGF 165 b using siRNA (Fig. 6e, g and Supplementary Figures 8a and 8b) . These data strongly suggested that VEGF 165 b also triggers invasive functions upon bevacizumab treatment.
Finally, we investigated the contribution of the cross-talk between VEGF 165 b, VEGFR2, and β1 integrin to the response to bevacizumab. We found that bevacizumab treatment slightly but reproducibly induces β1 integrin activation (Fig. 7a ) and more importantly stimulates the formation of a complex between activated β1 integrin and VEGFR2, which was prevented by the knockdown of VEGF 165 b (Fig. 7b) . In addition, the knockdown of β1 integrin was found to prevent the formation of actin stress fibers (Supplementary Figure 9a Figure 9c) upon treatment. Taken together, these results highly suggested that the cross-talk between VEGF 165 b, β1 integrin, and VEGFR2 proteins leads to an invasive phenotype in lung adenocarcinoma cell lines in response to bevacizumab treatment.
Discussion
The VEGF 165 b splice variant has been shown to inhibit angiogenic signaling of VEGF 165 , and its downregulation in primary melanoma was associated with subsequent metastasis [14, 19, 20, 28] . It has not previously been shown to be upregulated in cancer, rather it is generally considered to be reduced as a proportion of total VEGF-A. In contrast, we find high levels of endogenous VEGF 165 b protein in a significant proportion of lung adenocarcinoma. Furthermore, we observe an association between a high VEGF 165 b/ VEGF 165 ratio and lymph node metastases. Therefore, in parallel with VEGF 165 triggering both invasive and antiinvasive functions [11] , we highlight a complex role of VEGF 165 b in tumors. In this new scheme, VEGF 165 b cannot be viewed solely as a tumor suppressive anti-angiogenic factor, but has now also to be considered to be able to be an endogenous tumor-promoting factor when cancer cells . i H1299 were plated onto fibronectin glass coverslips for 24 h and treated, or not, for 1 h with rhVEGF 165 b (1 ng/ml). Co-immunofluorescence analyses of activated β1 integrin (clone 9EG7, green) and phosphopaxillin(Tyr118) (red) were performed. DAPI was used to counterstain the nucleus. Histograms representing quantification of cells exhibiting focal adhesion was performed on at least 300 cells (Mann-Whitney test) *p < 0.05. Scale bar = 20 µm express VEGFRs. Importantly, we demonstrate that autocrine rather than paracrine functions of VEGF 165 b are involved in this setting.
We provide the first evidence that VEGF 165 b stimulates the proliferation and invasion of lung tumor cells. Importantly, we confirm the results in tumor xenografts and show that this is associated with a modulation of the KI67 proliferative index, while CD31 or α−SΜΑ endothelial staining, two markers of tumor neo-angiogenesis, do not significantly vary. Paradoxically, we previously demonstrated that overexpression of VEGF 165 b correlates with reduced angiogenesis in lung adenocarcinoma xenografts [29] . In this former report, we only investigated the early paracrine effects of VEGF 165 b on neo-angiogenesis, as mice were sacrificed 7 days after induction of VEGF 165 b. In the current study, mice were sacrificed 41-45 days after tumor cells injection, thereby supporting the idea that autocrine tumor-promoting functions of VEGF 165 b may surpass its paracrine anti-angiogenic functions to promote lung tumor growth (Fig. 8) . Our results are in agreement with Catena and co-workers who noticed that stable overexpression of VEGF 165 b promotes the development of lung ADC xenografts without affecting the vascular density [17] . In addition, our data are consistent with previous observations in various tumors such as renal cell carcinoma [30] or infiltrating breast carcinoma [17] , where VEGF xxx b isoforms are not always downregulated. On the other hand, VEGF 165 b was also reported to slowdown the growth of colon cancer xenografts through inhibition of tumor neovascularization, without any effects on tumor proliferative rate [31] [32] [33] .
Therefore, whether VEGF 165 b exerts anti-versus protumoral functions may depend on the tumor type. One plausible but not exclusive explanation of these dual functions could come from the expression level of VEGFR receptors in tumors. In lung cancer that expresses VEGFR1/ 2 [6] , we show that VEGF 165 b increases VEGFR1 and VEGFR2 mRNA levels, and triggers a sustained phosphorylation of both receptors which correlates with ERK1/2 and p38MAPK activation. In addition, we demonstrate that VEGF 165 b induces a β1 integrin/VEGFR2/FAK/cofilin signaling pathway that promotes actin stress fiber formation and show that β1 integrin is required for the invasive functions of VEGF 165 b. Taken together, these data provide a molecular rationale for the previous observation that upregulation of β1 integrin correlates with advanced stages, lymph node metastases, increased relapse rate, and decreased OS in lung adenocarcinoma patients [34] .
The identification of predictive biomarkers of response to anti-angiogenic therapies is a crucial issue in the clinic. Even though these therapies were initially developed to target endothelial cells only, it is of prime importance to evaluate their impact on tumor cells themselves. In this study, we show that anti-angiogenic therapies combined (or not) with platinum salts regulate VEGF-A alternative premRNA splicing and specifically increase VEGF 165 b levels in lung adenocarcinoma cell lines. In addition, we demonstrate that bevacizumab activates the VEGF 165 b/β1 integrin/ VEGFR signaling network, leading to an invasive phenotype. Therefore, besides its ability to promote lung tumor growth, VEGF 165 b appears to be also a determinant of the response to anti-angiogenic therapies. In this setting, our results support the very recent observation that integrin alpha 9 (ITGA9), known to form a heterodimeric receptor with activated β1 integrin, belongs to a ten-gene signature that predicts the outcome in advanced non-squamous NSCLC patients treated with a combination of bevacizumab and erlotinib [35, 36] . They also fit well with the previous demonstration that β1 integrin and its downstream effector kinase FAK are activated in bevacizumab-resistant glioblastoma patients and contribute to bevacizumab resistance [37, 38] .
To conclude, we propose that a VEGF 165 b/VEGFR/β1 integrin autocrine loop contributes to the resistance of NSCLCs to anti-angiogenic therapies by promoting an invasive phenotype. This model is distinct but not contradictory to the results of Bates and colleagues who proposed that colon carcinoma patients exhibiting low levels of VEGF 165 b are more sensitive to bevacizumab + FOLFOX treatment compared with FOLFOX alone [25] . In that case, paracrine rather than autocrine functions of VEGF 165 b are presumed to be at play. As a whole, these and our data highlight the need for addressing the respective status of VEGF-A splice variants and their paracrine/autocrine 165 or rhVEGF 165 b (0.1 ng/ml) for 60 min. IgG was used as an irrelevant antibody. Total amount of β1 integrin in protein extracts was assessed by western blotting (lower panels). Numbers represent the results of densitometric quantification of the signal using imageJ software. The ratio of activated β1 integrin: total β1 integrin in untreated cells was arbitrarily assigned the value 1. d β1 integrin activation measured by flow cytometry in H358 or H1299 cells treated, or not (NT), for 1 h with rhVEGF 165 b (10 ng/ml). The mean ± SDs of four independent experiments are presented. (nonparametric Mann-Whitney test). e F-actin staining using phalloidin-TRITC in H1299-VEFG 165 
b (1 ng/ml). Co-immunofluorescence staining was performed to detect β1 integrin (green) and phospho-paxillin(Tyr118) (red). DAPI was used to counterstain the nucleus. Of note, the green fluorescence strongly decreased in β1 integrin knocked-down cells, consistent with the efficiency of β1 integrin knockdown. Scale bar = 20 µm. (g) A wound healing assay was performed in H1299-VEFG 165 b clones transfected with control (siMis) or siRNA against β1 integrin (siβ1). Scratch recovery was estimated after 13 h. The right panel represents the scratch coverage percentage. n = 3 independent experiments. Values are mean ± SD (non-parametric Mann-Whitney test) *p < 0.05. h H1299 were transfected for 72 h with mismatch (siMis) or β1 integrin (siβ1) siRNA in the presence or absence of rhVEGF 165 b (0.1 ng/ml) as indicated. Western blot analysis of the indicated proteins was performed. Tubulin was used as a loading control. i, j Immunoprecipitation of (i) β1 integrin or (j) VEGFR2 was performed in H358 cells treated, or not, with increasing amounts (0.1, 1 ng/ml) of rhVEGF 165 b for 1 h. IgG was used as an irrelevant antibody. Numbers represent the results of densitometric quantification of the signal using imageJ software. For VEGFR2 and β1 integrin interaction, the VEGFR2:β1 ratio was calculated in each condition. The value 1 was arbitrarily assessed in untreated conditions 
Materials and methods

Patients, tissue samples and serum
Seventy-six human non-small cell lung carcinoma (NSCLC) and 17 matched normal lung parenchymas were included in this study (Supplementary Table 1 and Supplementary Figures 1 and 2 ). Tissue banking and research conduct followed the national ethical guidelines and were approved by the Ministry of Research (approval AC-2010-1129) and the regional IRB (CPP 5 Sud Est). Histopathology diagnosis was made on formalin-fixed, paraffinembedded samples using the current WHO classification [39, 40] . For quantification of VEGF 165 b in sera, blood samples from nine healthy subjects and ten patients with chemotherapy-naive ADC enrolled in the Pharmacogenoscan study (NCT00222404; Grenoble University Hospital) were used [41] . Informed consent was obtained from all subjects.
Immunohistochemistry
Antibodies recognizing specifically VEGF 165 or VEGF 165 b splice isoform were produced by immunizing rabbits with synthetic peptides specific of the C-terminal part of either VEGF 165 (LNERTCRCDKPRR) or VEGF 165 b (LNERTCRSLTRKD) protein (Covalab, Villeurbanne, France). The other antibodies used for immunohistochemistry are listed in Supplementary Table 2 . Immunostaining was performed on 7-μm tissue sections, as described previously [42, 43] , and assessed by a pathologist (EB) who was blinded to the group allocation when scoring. Scoring [42, 44] . Wound healing assays were performed using fourwell lab-tek chamber Permanox® slides, previously coated with fibronectin (10 µg/mL) and visualized using an inverted microscope equipped with a camera MicroMAX N/B (Princeton Instruments). Invasion assays in transwells using 50 ng/mL β-FGF as a chemoattractant and analysis of the activity of MMP9 using gelatin zymography were performed as previously described [45, 46] . Immunofluorescence studies for activated β1 integrin (using 9EG7 antibody), phospho-paxillin(Tyr118) and F-actin were performed on cells coated onto 2 µg/ml fibronectin, fixed in 4% PFA, and permeabilized, or not, with PBS 1 × /Triton 0.2%. Cells were then mounted in a solution containing 4,6-diamino-2-phenylindole (DAPI) (Roti ®-Mount FluorCare DAPI, ROTH) and visualized by fluorescent microscopy using Axioimager microscope (Carl Zeiss, Jena, Germany) with the AxioVision® software at a 60x magnification and processed with ImageJ software.
Analysis of activated β1 integrin by flow cytometry
Cells re-suspended in PBS/BSA 1% (either with or without Mn2+ 0.5 mM) to induce β1 integrin activation were incubated with the primary antibody HUTS4 (MAB2079Z, Sigma-Aldrich) for 30 min. After two washes with PBS, the cells were incubated with Alexa 488 anti-rat antibody, fixed with 4% PFA, and re-suspended in PBS before flow cytometry analysis. The percentage of β1 integrin activation was calculated using the formula: % activation = (Mean FL1-A [Ac] / Mean FL1-A [Ac + Mn2 + ]) x 100. [29] ), as well as pro-tumoral functions on tumor cells themselves through the activation of a β1 integrin/VEGFR autocrine loop (this study). We propose that in the later stages of tumor development, the pro-tumoral proliferative functions of VEGF 165 b may bypass the anti-tumoral angiogenic ones to promote tumor progression. VEGF 165 b-expressing tumor cells also acquire more aggressive and invasive features, as evidenced by the appearance of EMT markers, that could contribute to the metastatic spreading of tumor cells. Anti-angiogenic therapies impact on VEGF-A pre-mRNA splicing and favor the expression of VEGF 165 b in tumor cells that could promote their escape from treatment. Based on the preliminary results indicating that VEGF 165 b-overexpressing cells are also more resistant to hypoxia, we propose that hypoxia induced by anti-angiogenic therapies may also contribute to the emergence of VEGF 165 b-expressing tumor cells. As a whole, our data suggest that modulating VEGF-A pre-mRNA splicing together with β1 integrin signaling might offer alternative therapeutic strategies to overcome resistance to anti-angiogenic therapies in lung adenocarcinoma ELISA assays VEGF 165 b was quantified on cellular extracts, cellular supernatants or serum using the R&D system Duoset ELISA kit (cat#DY3045), and pan-VEGF using either the Human VEGF Standard ELISA Development Kit from PeproTech (cat# 900-K10) or the ELISA assay from R&D System (DVE00).
RNA interference, RNA extraction, and quantitative RT-PCR β1 integrin silencing was performed using SMARTpool siGENOME ITGB1 siRNA (Dharmacon) and Oligofectamine RNAi max (Invitrogen). The siRNA specifically targeting VEGF 165 b was: forward, 5'-GAACGUACUUGCAG AUCUCUC-3'; reverse, 5'-GAGAGAUCUGCAAGUACG UUC-3'. The scrambled siRNA oligonucleotides used as a control for all RNA interference experiments were as follows: forward 5'-UCGGCUCUUACGCAUUCAA-3' and reverse 5'-CAAGAAAGGCCAGUCCAAG-3' or ON-TARGET plus non-targeting control pool (Dharmacon). Transfection was performed using Oligofectamine TM reagent (Invitrogen) and cells were analyzed 72 h posttransfection. The sequence for control siRNA used in in vivo experiments was designed as forward, 5'-CUUAC GCUCACUACUGCGA-3' and reverse, 5'-UCGCAGUA-GUGAGCGUAA-G-3'. Total RNA was extracted using Trizol ® reagent (Invitrogen) and subjected to reverse transcription using iScript TM Reverse Transcription Supermix (BIO-RAD). Quantitative PCR was performed with GoTaq ® qPCR Master Mix (Promega). VEGFR1/FLT1 (Hs.654360) and VEGFR2/KDR (Hs.479756) primer assays were purchased from TEBU-Bio (Le Perray-en-Yvelines, France). Relative gene expression was calculated, for each sample, as the ratio of specific target gene to GAPDH gene (reference gene), thus normalizing the expression of the target gene for sample to sample differences in RNA input.
Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitation experiments were performed as previously described [47] . The antibodies used are listed in the Supplementary Table 2 . Sera for immunoprecipitation or detection of total (serum 227) or activated (TS2/16) β1 integrin were provided by Dr Corinne Albiges-Rizo (Institute For Advanced Biosciences, La Tronche, France). For immunoprecipitation, 5 mM sodium molybdate was added to the lysis buffer to enhance the cross-linking of the complexes. Irrelevant rabbit or mouse IgG was used as a control for immunoprecipitation. Immunoblots were quantified using ImageJ software, and the mean ± standard deviation of at least three independent experiments was calculated. Owing to space constraints in some main figures, quantification of western blotting experiments is also provided in Supplementary Figure 10 and Supplementary Figure 11 .
In vivo studies
All animal experiments were conducted in agreement with the 'Principles of Laboratory Animal Care' (NIH publication n°86-23, revised 1985) and were approved by the ComEth Grenoble ethic committee (n°of approval 165_IAB-U823-MK-11). In all experiments, H358, H358-Tet-On, H358-SRSF6, H1299-Luc, or H1299-Luc-VEGF 165 b cells were implanted subcutaneously (10-20 × 10 6 cells) into 5-6 weeks-old female Nmri nude mice (Janvier, Le Genest-Isle, France). Tumor volumes were measured once a week as previously described [48] . H358 cells were allowed to form tumors for 3-4 weeks. When tumor volumes reached 30-40 mm 3 , mice were weighed, randomly divided into four homogeneous groups according to their weight (10 mice each), and were alternatively SC-or IP-injected 4 times a week with either mismatch siRNA as a control or VEGF 165 b siRNA. Once a week, siRNAs were combined with either bevacizumab (7.5 mg/kg) or PBS as a control. Transfection of siRNA was performed using in vivo-jetPEI™-Gal (Polyplus-transfection). Tumor volumes were monitored throughout the experiment. In all experiments, the investigators (AB, SG, MK, and MG) were blinded to the group allocation during the experiment and when assessing the outcome. Mice were sacrificed after 6 weeks of treatment, tumors were removed, photographed, weighed, washed, fixed in buffered formaldehyde, and processed for immunohistochemical analysis as previously detailed. Immunostainings were quantified using ImageJ software as previously described [49] . In some experiments, tumoral samples were lysed in RIPA buffer supplemented just before use with proteases and phosphatases inhibitors, and western blot experiments were performed on these samples. Statistical analysis of tumor volumes between the groups was performed using a two-tailed non-parametric MannWhitney t test (at least nine animals per group).
Statistical analyses
In all in vitro experiments on cell lines, at least three independent experiments were performed. MTS, apoptosis, and proliferative and ELISA assays were always done in duplicate or triplicate for each experiment. Non-parametric, two-tailed Mann-Whitney or ANOVA tests were performed using Statview (Abacus Concepts) or Prism software. Descriptive analyses comparing continuous and two-level categorical variables were carried out using the MannWhitney test. P-values < 0.05 were considered significant.
